Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $0.19.

  • Corcept Therapeutics' EPS (Basic) fell 5777.78% to $0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0, marking a year-over-year decrease of 2647.06%. This contributed to the annual value of $1.35 for FY2024, which is 3270.41% up from last year.
  • Per Corcept Therapeutics' latest filing, its EPS (Basic) stood at $0.19 for Q3 2025, which was down 5777.78% from $0.33 recorded in Q2 2025.
  • Corcept Therapeutics' EPS (Basic)'s 5-year high stood at $0.45 during Q3 2024, with a 5-year trough of $0.15 in Q4 2022.
  • Moreover, its 5-year median value for EPS (Basic) was $0.27 (2023), whereas its average is $0.26.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 10000.0% in 2023, then plummeted by 5777.78% in 2025.
  • Corcept Therapeutics' EPS (Basic) (Quarter) stood at $0.28 in 2021, then plummeted by 46.43% to $0.15 in 2022, then surged by 100.0% to $0.3 in 2023, then dropped by 1.87% to $0.29 in 2024, then crashed by 35.46% to $0.19 in 2025.
  • Its EPS (Basic) was $0.19 in Q3 2025, compared to $0.33 in Q2 2025 and $0.19 in Q1 2025.